Last reviewed · How we verify

NCT04674228

Review of Post-Study Clinical Endoscopy Reports in Follow Up to MAY2016-07-01

Completed Last updated 16 June 2022
What this trial tests

trial testing Electronic Health Record Review in Familial Adenomatous Polyposis in 42 participants. Completed in 17 May 2022.

Timeline
7 May 2021
Primary endpoint
28 October 2021
17 May 2022

Quick facts

Lead sponsorNational Cancer Institute (NCI)
StatusCompleted
Study typeOBSERVATIONAL
Enrollment42
Start date7 May 2021
Primary completion28 October 2021
Estimated completion17 May 2022
Sites2 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute (NCI)

Who can join

Eligibility, any sex, with Familial Adenomatous Polyposis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study reviews post study clinical endoscopy reports in follow up to patients who participated in MAY2016-07-01 with weekly erlotinib for familial adenomatous polyposis. Reviewing follow up medical records may help researchers examine the extent of rapid progression of familiar adenomatous polyposis disease burden after discontinuation of weekly erlotinib.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Electronic Health Record Review

Trials testing the same drug.

Other recruiting trials for Familial Adenomatous Polyposis

Currently open trials in the same condition.

Other National Cancer Institute (NCI) trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04674228.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing